Benzene, 3-chloro-1-methyl-4-(1-methylethenyl)

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzene, 3-chloro-1-methyl-4-(1-methylethenyl)
• 英文别名: 2-chloro-4-methyl-1-prop-1-en-2-ylbenzene
• 化学式: C₁₀H₁₁Cl
• 分子量: 166.65
• InChiKey: SIZLKNFNLHRNGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] TRICYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2018102634A1

  公开（公告）日：2018-06-07

  The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, Y, Z, R1, R7A, R7B and R8 are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.

  本发明涉及式(I)的三环杂环化合物及其药学上可接受的盐或前药，其中A、X、Y、Z、R1、R7A、R7B和R8如本文所定义。本发明还涉及包含至少一种三环杂环化合物的组合物，以及使用这些三环杂环化合物治疗或预防受试者的HIV感染的方法。
• [EN] AMIDE DERIVATIVES OF BENZENE-SULFONANILIDE, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR CANCER TREATMENT USING THE SAME<br/>[FR] DÉRIVÉS AMIDE DE BENZÈNE-SULFONANILIDE, COMPOSITION PHARMACEUTIQUE LES CONTENANT ET MÉTHODE DE TRAITEMENT DU CANCER LES UTILISANT
  申请人：UNIV STATE CLEVELAND

  公开号：WO2012054417A1

  公开（公告）日：2012-04-26

  The invention provides a compound of formula (I), a pharmaceutical composition thereof, a method of preparing a medicament for the treatment of a cancer, and a method of treating cancers. The invention exhibits merits against cancers such as significantly higher potency and effectiveness over a broader range of cancers. In formula (I), Ra is a benzyl group with alkyl and/or alkoxy; Rb is selected from H and alkyl groups; Rf is an alkyl; and R3 is selected from a (Formula) substituted phenyl, a heterocyclic group, and, Formula, wherein Rc is selected from a fused ring, fused rings, and any bivalent cyclic group. Formula (I)